http://www.europeangas.com.au/newsDisplay/files/1307484688.pdfArrowhead gives EPG a fair share value bracket of $1.42 - $1.75
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%